Metastatic Potential of Cells in Breast Tumors

New research has revealed that breast tumors contain a small population of cells with the inherent capacity to initiate metastasis, even in early-stage disease, offering fresh insight into how cancer spreads and potentially guiding future detection and treatment strategies.

The findings, published in the journal Nature Cancer on April 15, 2026, stem from a collaborative study led by scientists at the Memorial Sloan Kettering Cancer Center in New York and the Broad Institute of MIT and Harvard. Using advanced single-cell RNA sequencing and lineage tracing techniques in mouse models of breast cancer, researchers identified a distinct subpopulation of tumor cells expressing a specific genetic signature linked to metastatic potential.

These cells, termed metastasis-initiating cells (MICs), were found not only in aggressive, late-stage tumors but also in a subset of early-stage lesions traditionally considered low-risk. Importantly, the presence of these cells correlated with eventual spread to distant organs such as the lungs, liver, and bones, even when standard clinical markers failed to predict such outcomes.

“We’ve long known that metastasis is a inefficient process, with only a tiny fraction of cancer cells capable of surviving in the bloodstream and forming new tumors,” said Dr. Elena Rodriguez, co-senior author of the study and a computational biologist at the Broad Institute. “What’s surprising is that these cells are present much earlier than we thought, and they carry a detectable molecular fingerprint that could one day help us identify patients at hidden risk.”

Understanding the Metastatic Potential in Early Disease

Metastasis remains the leading cause of death in breast cancer patients, accounting for approximately 90% of fatalities. Despite advances in early detection and treatment, predicting which patients will develop metastatic disease remains a significant clinical challenge. Current tools rely on tumor size, lymph node involvement, and molecular subtypes, but these factors do not always capture the biological propensity for spread.

The study addressed this gap by focusing not on tumor bulk, but on rare cellular states within tumors that may drive dissemination. By analyzing over 200,000 individual cells from primary breast tumors in mice and validating findings in human tumor samples from the Cancer Genome Atlas (TCGA), the team identified a consistent transcriptional profile associated with MICs. This profile included upregulation of genes involved in extracellular matrix remodeling, epithelial-to-mesenchymal transition (EMT), and stress resistance — pathways known to facilitate invasion and survival in circulation.

Clinical Implications and Limitations

While the discovery does not immediately change clinical practice, it opens avenues for refining risk stratification. Researchers suggest that if similar MIC signatures can be reliably detected in liquid biopsies or minimally invasive tissue samples, it might one day help identify early-stage patients who could benefit from more aggressive adjuvant therapy — even if their tumors appear small or lymph node-negative on conventional imaging.

“This isn’t about overtreating everyone. It’s about finding the few who need more intensive intervention because their tumors harbor cells that are primed to spread, even if the main mass looks benign by current standards.”

Dr. James Lin, oncologist at Memorial Sloan Kettering and co-senior author

The researchers caution that the work is primarily preclinical. While human tumor data showed enrichment of the MIC signature in samples from patients who later developed metastases, prospective clinical trials are needed to determine whether detecting these cells improves outcome prediction or guides therapy effectively.

Future Directions in Cancer Detection

Experts not involved in the study noted the importance of the findings but emphasized the need for caution. Dr. Amara Patel, a breast cancer specialist at the Dana-Farber Cancer Institute who reviewed the paper, said the study “elegantly demonstrates a biological mechanism underlying early metastatic competence” but added that translating MIC detection into a clinical tool will require standardization, validation across diverse populations, and integration with existing diagnostic frameworks.

Ongoing efforts are already underway to adapt the MIC signature for use in circulating tumor cell (CTC) assays and epigenetic blood tests. Several biotechnology firms have expressed interest in developing assays based on the gene panel identified in the study, though none have yet received regulatory approval for clinical use.

The study was funded by grants from the National Institutes of Health (NIH), the Breast Cancer Research Foundation, and the Howard Hughes Medical Institute. All animal procedures were conducted in accordance with institutional ethical guidelines, and human data were accessed through de-identified, publicly available repositories with appropriate oversight.